Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring.

Fumi Uemura, Yosuke Okada, Keiichi Torimoto, Yoshiya Tanaka
Author Information
  1. Fumi Uemura: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
  2. Yosuke Okada: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
  3. Keiichi Torimoto: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
  4. Yoshiya Tanaka: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. tanaka@med.uoeh-u.ac.jp.

Abstract

Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value.

References

  1. Diabetes Care. 2019 Mar;42(3):400-405 [PMID: 30352896]
  2. J Clin Endocrinol Metab. 2013 May;98(5):1845-59 [PMID: 23589524]
  3. Diabetes Obes Metab. 2015 Jun;17(6):533-540 [PMID: 25678212]
  4. Diabetes Care. 2010 Sep;33(9):1913-8 [PMID: 20551017]
  5. Lancet. 1998 Sep 12;352(9131):837-53 [PMID: 9742976]
  6. J Diabetes Investig. 2018 Jul;9(4):925-936 [PMID: 29171937]
  7. Diabetes Care. 2017 May;40(5):663-670 [PMID: 28223296]
  8. J Diabetes Investig. 2021 Feb;12(2):244-253 [PMID: 32594655]
  9. Diabetes Technol Ther. 2018 Feb;20(2):140-146 [PMID: 29293363]
  10. Diabetes Care. 2011 Apr;34(4):795-800 [PMID: 21335621]
  11. J Diabetes Investig. 2020 Jan;11(1):257-261 [PMID: 31729165]
  12. Diabetes Technol Ther. 2018 Sep;20(9):603-612 [PMID: 30070933]
  13. J Diabetes Investig. 2020 Mar;11(2):417-425 [PMID: 31461223]
  14. Diabetes. 2003 Nov;52(11):2790-4 [PMID: 14578298]
  15. J Diabetes Complications. 2017 Jun;31(6):1047-1052 [PMID: 28389158]
  16. Diabetes Care. 2019 Aug;42(8):1593-1603 [PMID: 31177185]
  17. Diabetes Metab. 2019 Oct;45(5):446-452 [PMID: 30763700]
  18. Diabetes Metab. 2018 Sep;44(4):313-319 [PMID: 29602622]
  19. J Diabetes Investig. 2010 Oct 19;1(5):212-28 [PMID: 24843435]
  20. JAMA Intern Med. 2016 Jul 1;176(7):969-78 [PMID: 27273792]
  21. Sleep. 2018 Jul 1;41(7): [PMID: 29746662]
  22. Diabetol Metab Syndr. 2019 Feb 15;11:18 [PMID: 30815039]
  23. Diabetes Ther. 2018 Oct;9(5):1969-1977 [PMID: 30136074]
  24. Diabetes Care. 2017 Jul;40(7):832-838 [PMID: 28039172]
  25. J Adv Nurs. 2018 Oct;74(10):2373-2380 [PMID: 29917259]
  26. Diabetes Metab. 2018 Mar;44(2):97-100 [PMID: 29153486]
  27. Diabetes Care. 1990 Feb;13(2):133-42 [PMID: 2190769]
  28. J Diabetes Investig. 2017 May;8(3):397-410 [PMID: 28349643]

MeSH Term

Aged
Blood Glucose
Blood Glucose Self-Monitoring
Cross-Sectional Studies
Diabetes Mellitus, Type 2
Female
Humans
Hypoglycemic Agents
Middle Aged
Sulfonylurea Compounds

Chemicals

Blood Glucose
Hypoglycemic Agents
Sulfonylurea Compounds

Word Cloud

Created with Highcharts 10.0.0SUglycemicglucosevariabilityTBR < 54treatment2T2DMwell-controlledlevelpatientsidentifiedTIRcontinuousmonitoringCGMtypestudyendpointdifferencenon-SU%CVgrouphigh-doseβ:p = 0usesulfonylurea-treatedTimerangeindexcontrolobtainedaimcomparesulfonylureasSUsdiabetesmellitusTIR > 70%subjects123selectedunderwent24 hadmissionwithoutchangingprimarysecondarytimerange < 54 mg/dLn = 63n = 60groupsstandarddeviationpercentagecoefficientvariationmaximumhigherlongersignificantfactoraffected678034High-dosecontributedprolonged0487028enlargedassociatedresultshighlightneedcarefuladjustmentdoseirrespectiveglycatedhemoglobinvalueEnlargeddiabeticsusing

Similar Articles

Cited By (4)